Durability of Boosted Atazanavir (ATV) or Darunavir (DRV) Plus Maraviroc (MVC) Dual rescue Therapy in Poorly Adherent Subjects in View of Long-Acting Drugs
Amedeo Capetti(Luigi Sacco Hospital), Giuliano Rizzardini, Simona Landonio(ASST Fatebenefratelli Sacco), Gianfranco Dedivitiis(Luigi Sacco Hospital), Stefania Vimercati(Qinetiq (United Kingdom)), Noemi Astuti, Fosca Niero(Luigi Sacco Hospital)
Cited by 1
Related Papers
Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection
|New England Journal of Medicine|2022|264
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
|Journal of Hepatology|2018|133
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|115
Incidence of Adverse Reactions in HIV Patients Treated With Protease Inhibitors: A Cohort Study
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2000|97